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Meta-analyses and overviews performed by the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) emphasized the
pivotal role of tamoxifen as adjuvant hormonal treatment in early
breast cancer patients with positive oestrogen receptors (ER)
(Fisher et al, 1997; EBCTCG, 1998). This effect was observed
regardless of age and tended to increase with treatment duration
(greater effect with longer treatment) and with time as both the
improvement in survival and the reduction of controlateral breast
cancer went on throughout the first 10 years (EBCTCG, 1998).
However, the incidence of endometrial cancers also increased with
the duration of tamoxifen treatment (EBCTCG, 1998). The same
EBCTC group also demonstrated the value of adjuvant oophorec-
tomy in premenopausal women suffering from a primary breast
cancer (EBCTCG, 1996); further trials showed that the adjuvant
effect of oophorectomy was restricted to ER-positive tumours
(Stewart and Everington, 1995). 
In metastatic breast cancer, tamoxifen has been the preferred
primary endocrine treatment, particularly for post-menopausal
women, for many years (Rubens, 1993). Comparative evaluations
of the relative efficacy of tamoxifen and progestogens (especially
at high dosages) provided evidence of an at least equipotent or
even better antitumoural activity of the progestogens (Mattson,
1980; Löber et al, 1981; Van Veelen et al, 1986; Muss et al, 1988;
Muss et al, 1990; Castiglione-Gertsch et al, 1993; Gill et al, 1993).
Moreover, after having crossed-over, progestogens retained some
antitumour efficacy after tamoxifen’s failure (Mattson, 1980;
Löber et al, 1981; Van Veelen et al, 1986; Muss et al, 1988; Muss
et al, 1990; Castiglione-Gertsch et al, 1993; Gill et al, 1993). Some
trials (Castiglione-Gertsch et al, 1993) suggested that tamoxifen’s
primacy may be challenged particularly by the use of progestogens
in patients suffering from bone metastases (Muss et al, 1988; Muss
et al, 1990; Castiglione-Gertsch et al, 1993; Gill et al, 1993). In
those trials, as already observed, the dose of progestogen
(Mattson, 1980; Löber et al, 1981; Cavalli et al, 1984;
Tchekmedyian et al, 1986; Van-Veelen et al, 1986) could be of
paramount for determining the antitumor efficacy of these agents:
high doses of drugs could significantly increase the response rate
and even, in some observations, prolong time to treatment failure
and survival (Mattson, 1980; Löber et al, 1981; Cavalli et al, 1984;
Tchekmedyian et al, 1986; Van Veelen et al, 1986). Furthermore,
like first-line hormonotherapy for advanced ER positive breast
cancers, in premenopausal patients, HD-MPA developed anti-
tumour activity at least equivalent, if not superior, to oophorec-
tomy (Martoni et al, 1991). The addition of medroxyprogesterone
acetate in high dosage (i.e. at least 500 mg day–1) to combined
chemotherapy also enhanced initial tumour shrinkage and perhaps
prolonged survival in advanced breast carcinoma (Robustelli Della
Cuna et al, 1980; Löber et al, 1981). 
Although the action of progestins, such as high-dose medrox-
yprogesterone acetate (HD-MPA), can be explained by interacting
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http://www.bjcancer.comwith oestrogens, either by inhibition of gonadotrophin secretion or
down-regulation of the oestrogen receptors, they may also have a
direct inhibitory effect on tumour cell growth after binding to
progesterone receptors (Löber et al, 1981; Blossey et al, 1984;
Paridaens et al, 1986; Rubens, 1993; Hyder et al, 1998). HD-MPA
induces a significant blockage of the hypothalamo-hypophyso-
gonadal and adrenal axes (Blossey et al, 1984; van Veeler et al,
1985). Therefore, in premenopausal women, HD-MPA is able to
provide both castration and adrenal suppression (Löber et al, 1981;
Blossey et al, 1984; Van Veelen et al, 1985; Paridaens et al, 1986;
Rubens, 1993; Hyder et al, 1998). 
On those bases, in 1982, the Adjuvant Breast Cancer Project
Belgium initiated a multicentric randomized trial aiming at evalu-
ating the impact of adjuvant therapy with HD-MPA intramuscu-
larly administered in women submitted to surgery for early breast
cancer (Focan et al, 1986; Focan et al, 1989, 1990, 1995, 1996).
The treatment had been administered for 6 months in half of the
patients; node-positive patients received also CMF (IV; days 1 and 8)
during 6 months (Focan et al, 1986, 1990). We reported previously
on tolerance of treatments: haematological and general tolerances
to CMF were improved in the HD-MPA group; classical side-
effects of MPA (i.e., perspiration, tremor, cramps, fluid retention
or spotting) were recorded in 11–17% of patients who suffered an
average weight gain of 7.4 KGs vs 1.2 KGs under controls at the
same time (Focan et al, 1986; Wils, 1988; Focan et al, 1989, 1990,
1995, 1996). Women still menstruating usually developed tran-
sient amenorrhoea under MPA treatment; amenorrhoea under
CMF therapy was, on the other hand, almost universal over 40
years old (Focan et al, 1990, 1995); however detailed follows-up
of those phenomena were not mandatory in the trial. Moreover,
partly due to a myeloprotective effect of HD-MPA (Wils, 1988;
Focan et al, 1990, 1995), the patients receiving this treatment
experienced less delay and/or dose reductions of chemotherapy
regardless of age and could receive overall higher dose intensities
and dose-intensity products of CMF therapy. Younger patients
(<50 years) were also able to support higher doses of CMF than
older patients; this was observed both for dose intensities and
dose-intensity products (Focan et al, 1986; Hryniuk and Levine,
1986; Ng et al, 1989; Focan et al, 1990, 1995). In fact, patients
under MPA adjuvant treatment could receive about 90% of the
total chemotherapy foreseen while patients under CMF alone
received about 70% of the scheduled treatment (Focan et al, 1990,
1995). 
In this report, we present the results regarding the outcome of
patients (relapse-free and overall survivals) after a 13-year median
follow-up. Previous reports were published in full papers in books
of proceedings of meetings (Focan et al, 1990, 1995) or as
congress abstracts (Focan et al, 1996); the results at 3 years in
node-negative patients were the only developed in a peer-reviewed
journal (Focan et al, 1989). 
MATERIAL AND METHODS 
Detailed methodology was published previously (Focan et al,
1990, 1995). Briefly, patients under 70, with primary stage I or II
breast cancer and a Karnofsky index >60 were eligible for the trial;
axillary lymph node status (node-negative (NN) or node-positive
(NP)) had to be assessed on at least 5 nodes. Hormonal receptors,
when available, were assessed by the dextran-coated charcoal
assay. After either mastectomy or limited surgery, patients were
randomized to receive HD-MPA or no adjuvant treatment. The
HD-MPA treatment included an induction period (28 consecutive
daily i.m. injections of 500 mg MPA or 5 daily i.m. injections of
500 mg MPA weekly during 5 weeks) followed by a maintenance
treatment (500 mg i.m. twice per week during 5 months). Axillary
NP patients were also given CMF chemotherapy (cyclophos-
phamide 500 mg/m2 i.v., methotrexate 40 mg/m2 i.v. and 5-
fluorouracil 600 mg/m2 i.v., days 1 and 8, to be repeated every 4
weeks during 6 cycles). Actuarial survivals (relapse-free and
overall) were evaluated according to the Kaplan–Meier method
while applying Log-rank and Wilcoxon statistical tests (Kaplan
and Meier, 1958). Any first breast cancer relapse (local and/or
distant) was considered as an event for the RFS; every death
regardless of the cause was considered for the OAS. Finally, a
Cox’s proportional hazards regression analysis was conducted to
explain relapse-free and overall survivals as functions of indepen-
dent variables (Cox, 1972). 
RESULTS 
541 patients were randomized between 1982 and 1989: 260
patients in the NN group and 281 patients in the NP group among
whom respectively 246 and 270 were fully assessable. The reasons
for ineligibility or invalidity have been described elsewhere
(Focan et al, 1989, 1995, 1996). The characteristics of both groups
are recalled in Table 1. Every patients’ characteristic was well
balanced but one: a higher number of patients with 1–3 positive
axillary nodes and a lower number of patients with more than 4
involved nodes were included by chance within the CMF-alone
arm (Table 3). Patients had been followed up for a median time of
13 years. 
The relapse-free survival was significantly improved in the NN
group treated with HD-MPA (Table 3, Figure 1). After 13 years,
RFS was respectively 69% in the MPA group vs 54% in the
control group. This difference was confirmed regardless of age 
(< 50 years: + 22%; > 50 years: + 10%) and of any other prog-
nostic factor (such as T stage, receptors levels, menopausal status)
(Focan et al, 1989, 1990, 1995, 1996). However, this difference
could not be clearly translated into an improvement of overall
survival despite a significant difference after 5 years in each age
subgroup (Focan et al, 1990) and a border line significant effect in
favour of the adjuvant hormone arm in patients under 50 years 
(+ 16%) which was still detectable with more prolonged follow-up
(P = 0.06) (Table 3). 
Contrary to what was observed in NN patients, no difference
was noted in relapse or death rates for the whole group of NP
patients. However, when patients were split according to their ages
(<50;  > 50 years), clear-cut differences appeared (Table 3).
Indeed, patients under 50 years had a worse evolution when
treated with the association of CMF and MPA; in this group, not
only relapse-free (+30%) but overall survivals as well (+23%)
were quite significantly bettered in the group treated with CMF
alone. On the contrary, patients over 50 years who were treated
with the combined modality had a significantly improved relapse-
free interval (+25%) than those treated with CMF alone (Table 3;
Figure 2); overall survival of these patients remained marginally
improved (+9%). In NP patients as well, other prognostic determi-
nants (T stage, number of positive nodes, hormone receptor levels)
did not influence the results described above (Focan et al, 1989,
1990, 1995, 1996). In peculiar, no difference in RFS or OAS could
be assessed when patients were analysed according to the nega-
tivity (< 10 fmol mg–1 prot) or positivity (³ 10 fmol mg–1 prot) of
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Table 1 Characteristics of patients 
Node negative Node positive 
Control HD-MPA P CMF CMF + HD-MPA P
All evaluable patients 123 123 138 132 
Premenopausal 41 44 57 58 
Perimenopausal 10 18 18 10
Postmenopausal 66 52 NS 54 54 NS 
Unknown 6 9 9 10 
Age, years 
< 50 44 47 52 52 
³ 50 79 76 NS 86 80 NS 
Unknown 3 0 0 0 
T1 48 51 23 24 
T2 66 61 87 83 
T3 5 5 NS 19 21 NS 
Tx 4 6 9 4 
ER, fmol mg–1 prot 
< 10 28 26 41 27 
³ 10 51 43 NS 65 61 NS 
Unknown 44 54 32 44 
PgR, fmol mg–1 prot 
< 10 31 29 35 23 
> = 10 46 40 NS 70 64 NS 
Unknown 46 54 33 45 
Mastectomy 73 76 114 115 
Limited surgery 49 43 NS 19 16 NS 
Radiotherapy 
Yes 104 85 109 109 
No 17 35 < 0.05 26 23 NS 
Number of positive nodes 
1–3 – – 81 60 
4–9 – – 34 52 < 0.05 
> = 10 – – 19 19 
Unknown 4 1 
NS = not significant. 
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Figure 1 Actuarial relapse-free and overall survival in node-negative (NN) patients according to age (< 50: A, C; ³ 50: B, D). 
In abscissa, the probability of survival. In ordinate, the time in years (L-R: log-rank test; W: Wilcoxon test) the tumoral receptors (Focan et al, 1989, 1990, 1995, 1996).
However receptors levels were only assessed in 60–70% of cases;
then, the number of patients in some sub-groups might have been
too low to draw any statistical evaluation (see Table 1).
Furthermore, results both in younger and older patients were not
influenced by the number of positive nodes (Table 4); this obser-
vation assumed a special interest for node positive < 50-year-old
women, in whom a mean lower number of positive nodes was
expressed by chance in the CMF alone arm (Table 1). This could
have favoured the final outcome of those patients. However, older
patients presented a better evolution with the combined treatment
whatever the number of positive nodes (Table 4). 
Univariate analyses by the Kaplan–Meier estimates performed
on the whole group evidenced a significant influence of, on the
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Table 2 Distribution of node-positive patients according to number of
involved nodes and age 
CMF CMF + HD-MPA P
Age < 50 
N 1–3 33 23 
N 4–9 11 23 0.026 
N > 10 8 5 
Unknown 0 1 
Age > 50 
N 1–3 48 37 
N 4–9 23 29 0.115 
N > 10 11 14 
Unknown 4 0 
Table 3 Actuarial survival (probability ± standard error at 13 years) 
Node negative Node positive 
Control HD-MPA P CMF CMF + HD-MPA P
(123) (123) w lg (138) (132) w lg 
Relapse-free survival 
Whole group 0.54 ± 0.05 0.69 ± 0.05 0.005 0.01 0.46 ± 0.04 0.48 ± 0.05 NS NS 
< 50 years 0.52 ± 0.08 0.74 ± 0.07 0.02 0.03 0.64 ± 0.07 0.34 ± 0.07 0.03 0.01 
> 50 years 0.55 ± 0.07 0.65 ± 0.06 0.06 0.17 0.34 ± 0.06 0.59 ± 0.06 0.002 0.002 
Overall survival 
Whole group 0.70 ± 0.05 0.70 ± 0.05 NS NS 0.59 ± 0.05 0.56 ± 0.04 NS NS 
< 50 years 0.65 ± 0.08 0.81 ± 0.06 0.08 0.06 0.77 ± 0.06 0.54 ± 0.07 0.01 0.01 
> 50 years 0.73 ± 0.06 0.63 ± 0.06 NS NS 0.47 ± 0.06 0.56 ± 0.06 NS NS 
W = Wilcoxon test; lg = logrank test. 
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Figure 2 Actuarial relapse-free and overall survival in node-positive (NP) patients according to age (< 50 : A, C; ³ 50: B, D). 
In abscissa, the probability of survival. In ordinate, the time in years (L-R: log-rank test; W: Wilcoxon test) one side, the T stage on relapse-free survival (P < 0.02) in NN
patients and, on the other side, the number of positive axillary
lymphnodes (1–3; 4–9; ³10) on relapse-free (P = 0.005) and
overall (P = 0.01) survival in NP patients. In multivariate evalua-
tions (Table 5), treatment and ER-category (negative < 10 or posi-
tive ³ 10 fmol mg–1 protein) were independent variables in NN
patients. In node-positive patients, the number of positive nodes,
as categorized above, and the treatment were also pointed out
especially in under 50-year-old women. 
DISCUSSION 
In the present study, HD-MPA was administered intramuscularly.
When the study started in 1982, it was not known yet whether i.m.
and oral routes would have a similar antitumor effect for advanced
breast cancer. However, identical antitumor effects for each way of
administration were shown in 2 subsequent randomized trials 
in advanced disease (Paridaens et al, 1986; Beex et al, 1987).
Regarding pharmacokinetics, the i.m. route was thought to prolong
the exposure time of tumour cells (Blossey et al, 1984; Canney 
et al, 1988; Etienne et al, 1992). In an adjuvant situation, HD-MPA
intramuscularly given during 6 months would in fact accomplish
exposure to the drug for at least 3 months more (Blossey et al,
1984; Canney et al, 1988; Etienne et al, 1999). Regarding the
chosen dose, it was shown in advanced disease that no further
tumour regression could be obtained from daily MPA IM doses
over 500 mg during the loading phase (Robustelli Della Cuna et al,
1980; Tamassia et al, 1982). Moreover, in a randomized evalua-
tion, HD-MPA had developed a better antitumoral effect than that
with low dosages of the drug (Cavalli et al, 1984). Those findings
support our choice for both dose level and route of administration. 
From a general point of view, we estimate that we have no data
strong enough to develop definitive considerations on the results
regarding the level of receptors in tumours. In fact, the trial was
initiated in 1982, at a time when the determination of tumour
receptors was not routinely performed in the oncological practice
and when the dextran-coated charcoal assay was the only method
available in a few centres to which tumour samples of our study
were referred. Therefore, these assessments were not obtainable
for all tumours, especially smaller ones; so, hormone receptors
determination was lacking in 30–40% of our cases (Table 1). Then,
despite a sufficiently high number of patients to conclude at group
levels, we remain cautious regarding the results provided for 
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Table 4 Actuarial survival at 13 years according to age and number of positive nodes
(probability ± standard error at 13 years) 
CMF CMF + HD-MPA 
RFS OAS RFS OAS 
Age < 50
N 1–3 0.73 ± 0.08 0.80 ± 0.07 0.55 ± 0.11 0.64 ± 0.10 
N 4–9 0.55 ± 0.15 0.72 ± 0.13 0.20 ± 0.09 0.43 ± 0.10 
N > 10 0.31 ± 0.18 0.62 ± 0.17 0.40 ± 0.22 0.40 ± 0.22 
N > 4 0.44 ± 0.12 0.68 ± 0.11 0.18 ± 0.08 0.42 ± 0.09 
Age > 50
N 1–3 0.38 ± 0.07 0.57 ± 0.08 0.72 ± 0.08 0.68 ± 0.08 
N 4–9 0.32 ± 0.12 0.41 ± 0.13 0.47 ± 0.10 0.56 ± 0.10 
N > 10 0.18 ± 0.12 0.33 ± 0.15 0.35 ± 0.17 0.63 ± 0.13 
N > 4 0.28 ± 0.09 0.41 ± 0.10 0.45 ± 0.08 0.57 ± 0.08 
All P ³ 0.10 except for: 
RFS-Age ³ 50 N1–3: P = 0.038 (W); 0.014 (lg);  N ³ 10: P = 0.027 (W); 0.056 (lg);  N ³ 4:
P = 0.008 (W); 0.025 (lg); OAS-Age < 50 N1–3: P = 0.077 (W);  N ³ 4: P = 0.090 (W) 
Table 5 Multivariate analysis – Cox model 
Node negative Node positive 
RFS OAS RFS OAS 
Variables P Variables P Variables P Variables P
Whole Group Treatment 0.14 ER-cat 0.14 N Pos-cat 0.0097 N Pos-cat 0.003 
< 50 years Treatment 0.006 NS  N Pos-cat 0.002 N Pos-cat 0.002 
ER-cat 0.08 Treatment 0.09 Treatment 0.04 
Age 0.04 PGR-cat 0.12 
³ 50 years ER-cat 0.015 Age 0.11 Treatment 0.01 NS 
Treatment 0.04 
Age 0.07 
Notes: Variables with P ³ 0.15 were rejected by the model (quoted as NS not statistically significant). ER (PGR)-cat-oestrogen
(progestogen) receptor category (negative; positive ³ 10 fmol mg–1 prot; unknown not included). N Pos-cat = category of positive nodes
(0–3; 4–10; ³ 10) sub-groups, especially the premenopausal ones. In spite of these
restrictions, the tumour receptor level emerged as an independent
prognostic variable through the multivariate analysis (Table 5). 
Since we were specially interested to try to correlate some of
our results (especially in < 50 years patients) with the tumour
receptors levels, we have considered to reassess ER status by
immunohistochemical methods now routinely applied (Andersen,
1992; Pertschuk et al, 1994; Alberts et al, 1996). Every patient in
the study was analysed between 1981 and 1987 at a time when ER
status could not be routinely determined by immunohistochemical
techniques. Every retrospective assessment would be besmirched
by practical and methodological difficulties. Indeed, we would be
unable to correlate actual data with immunochemistry with
previous ones obtained with the dextran-coated charcoal assays.
Therefore, from a methodological point of view, survival analyses
considering immunohistochemical data would have to be
reassessed as separate subsets. Moreover, patients who were
entered in the trial were coming from many different hospitals
outside reference hospitals, in which they were treated. This would
seriously complicate the searches to obtain blank slides at the
present time. The pathologists are obliged by Belgian law to retain
paraffin-embedded sections of human samples for at least 15
years; this means that for patients included before 1985, we must
expect to discover that many samples are no further available.
From a pathological point of view, a considerable loss of
immunoreactivity has been observed in paraffin-embedded speci-
mens fixed in formaline or Bouin in comparison to sections from
frozen tissues (Andersen, 1992; Pertshuk et al, 1994). Moreover,
the majority of results shows discordances between dextran-coated
charcoal assay and immunohistochemical determinations in the
measurements of ER status in premenopausal females (Alberts
et al, 1996). This was precisely the group of patients for whom we
would have been interested to obtain more detailed information on
the receptors status due to the observed survival results. Finally, in
multivariate analysis, only ER status determined by dextran-
coated assay performed better than ER status assessed by immuno-
histochemistry as an independent prognostic variable regarding
disease-free and overall survival (Andersen, 1992; Alberts et al,
1996). Due to all these practical and methodological difficulties
and to the final split of patients in various prognostic subcategories
(basically regarding age), we considered that we would ultimately
not have interest in, a posteriori, reassessing the tumour receptors
levels by immunohistochemical methods. 
With a 13-year-median follow-up, we confirm previous reports
on the adjuvant activity of HD-MPA in NN early breast cancer
(Focan et al, 1989; 1990, 1995) with a better RFS, regardless of
age. Concerning survival, after a longer-term observation, only
women under 50 years seemed to benefit the most from the treat-
ment, since the early observed adjuvant effect tended to disappear
in older subjects. Precisely in premenopausal patients, according
to the multivariate assessment, the adjuvant impact of MPA seems
to be stronger (Focan et al, 1989, 1990, 1995; EBCTCG, 1998) in
patients with receptor-positive tumours (Table 5). 
These results must be considered in the light of those obtained
in premenopausal (or ≤ 50 years) women with adjuvant ovarian
ablation or tamoxifen use (EBCTCG, 1996; Fisher et al, 1997;
EBCTCG, 1998). The EBCTC group recently confirmed, in a
meta-analysis on more than 2000 women, the significant adjuvant
activity of an ovarian ablation; RFS and OAS were significantly
improved in the castrated group independently of the nodal status
(EBCTCG, 1996). This adjuvant effect seems to be limited to
receptor-positive tumours (Stewart and Everington, 1995). In
those patients, the magnitude of the benefit may equal that
obtained from an adjuvant chemotherapy (Stewart and Everington,
1995; Ejlertsen et al, 1999). The adjuvant effect of medical castra-
tion induced by LH-RH analogues, such as goserelin, may also be
potentiated by the concomitant use of tamoxifen (Rutqvist, 1999);
this association may even outshine the effect of CMF (Jakesz et al,
1999). At this point, it must be remembered that part of the 
HD-MPA hormonal activity could also be related to a general
hypophyseal adrenal and gonadal blockage; so, part of its antitu-
moral activity could be related to this castrative effect (Van Veelen
et al, 1985; Martoni et al, 1991; Paridaens et al, 1986). 
In ER-positive breast cancer patients, regardless of age, the
EBCTC group also confirmed a quite significant adjuvant impact
with an improvement of survival and a decrease of contralateral
breast cancer from the use of tamoxifen (EBCTCG, 1998). Of
interest, as reported for tamoxifen, we observed a sustained adju-
vant effect for both relapse-free and overall survival in younger
NN patients. In NN patients over 50 years, the significant decrease
in relapse-free survival observed after 5 years (Focan et al, 1990,
1996) tended to diminish and finally was not detectable any more
after 9 years. This transient effect was not translated into an
overall survival benefit and was in opposition with the observation
that in tamoxifen-treated patients the outcome improved with time
(EBCTCG, 1998). However our therapeutic programme was
limited to 6 months. This temporary exposition to MPA could have
been too short; for tamoxifen indeed, it was previously demon-
strated clearly that the longer the treatment the better the results in
terms of relapse or survival (5 years > 2 years > 1 year) (EBCTCG,
1998). 
In NP patients, we were puzzled with the results which were
clearly influenced by the age and/or the menopausal status of the
host. As those patients received also CMF chemotherapy, the
impact of the latter on the menstrual status of premenopausal
women as well as the biology and kinetics of the breast tumour has
to be questioned. Since the doses of chemotherapy were higher in
patients receiving MPA (Focan et al, 1995, 1996), especially in
younger ones (Focan et al, 1986, 1995, 1996), the hypothesis of a
dose–response relationship is not sustainable. In women under 50
years, the prognosis was better in the group under CMF only, which
had also received the lowest doses of chemotherapy. Therefore,
hormone manipulation with HD-MPA seemed to prevent the adju-
vant activity of chemotherapy in premenopausal patients although
higher dose levels of chemotherapy could be safely delivered.
Could MPA block cells outside the cell cycle (in G0–G1 phases)
and prevent then cytocidal activity of chemotherapy? Could the
general hypophyseal and adrenal axes blockages prevent the adju-
vant effect of chemotherapy in younger hosts? Could the hormonal
milieu influence outcome under combined treatment? We must
recall here that the general use of tamoxifen in premenopausal
breast cancer patients still remains a matter of discussion
(Andersson et al, 1999; Bramwell and Pritchard, 1999; Hutchins
et al 1999). In some groups of patients, its administration may be
harmful: this has been observed by several authors precisely when
a chemotherapy was administered concomitantly (Hutchins et al,
1999); this observation was obvious for receptor-negative tumours
(Andersson et al, 1999; Hutchins et al, 1999). In our trial, in post-
menopausal women or in women over 50 years the combined
modality approach improved the results achievable with the only
chemotherapy. This observation coincides with previous reports
suggesting the potentiation between chemo- and hormonotherapy
6 C Focan et al 
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early or advanced stages of the disease (Rubens, 1993). 
An unexpected imbalance in the number of positive nodes
between both arms of treatment was observed (Table 1 and 2).
Since the number of positive nodes was lower in the CMF arm,
especially in younger patients, we had to exclude a possible inter-
action between treatment and nodal status. In fact, this hypothesis
was not retainable: 
(1) because the imbalance regarding the number of involved
nodes was expressed partly in premenopausal, but also in
post-menopausal woman in whom the combined treatment
did better than CMF alone (Table 4); 
(2) because both in pre-and post-menopausal patients, exactly the
same trend in survivals (better for CMF alone in younger and
better for CMF + MPA in older subjects) was obvious, if the
impact of treatment was reanalysed after splitting subjects
according to the number of nodes (1–3; 4–9; > 10 or > 4)
(Table 4). Of course, due to the limited number of patients in
constructed sub-groups, some differences which were statisti-
cally significant when the whole group was considered were
no longer assessable, but they remain of the same relative
amplitudes as that of the whole group (Table 4). 
Several other trials assessed the value of adjuvant HD-MPA in NP
early breast cancer (Pannuti et al, 1988; Hupperets et al, 1993).
Observations similar to ours were obtained in NP patients treated
in 2 other trials with HD-MPA using a schedule comparable to
ours with a 6-month programme and CMF or FAC (5-fluorouracil,
adriamycin and cyclophosphamide) chemotherapy (Pannuti et al,
1988; Hupperets et al, 1993). In those trials, as well, only older
patients seemed to better benefit from the combined treatment
modality (Pannuti et al, 1988; Hupperets et al 1993; Focan et al,
1995). 
CONCLUSION 
Adjuvant HD-MPA therapy increased the relapse-free survival
(and overall survival in patients under 50 years) in NN early breast
carcinoma. In NP patients who also received CMF therapy, a posi-
tive effect was proved in patients over 50 years; in younger
patients (<50 years), the addition of HD-MPA to CMF
chemotherapy seemed detrimental. 
Based on our results, HD-MPA may be considered as an alter-
native hormonal adjuvant treatment instead of ovariectomy or
tamoxifen in the case of premenopausal or <50-year-old women,
preferably with ER-positive node-negative breast cancers. HD-
MPA may be proposed only with caution to early node negative 
> 50-year-old patients. In younger women with node-positive
cancer, candidates to chemotherapy, it may not be administered at
the same time as chemotherapy. The lack of global survival
improvement in patients over 50 despite a clear effect on relapse-
free survival may suggest that the duration of HD-MPA treatment
(6 months) had been too short. Therefore, since HD-MPA has a
scientific effect only on some patient’s categories and since the
clinical toxicity (i.e., an important weight gain) may be significant
(Focan et al, 1986, 1989, 1990, 1995), its routine use may not be
recommended without direct evaluation in relation to tamoxifen.
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